Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)

7033 Background: -7/del(7q) is associated with poor prognosis in MDS. In a recent phase III, randomized trial, AZA significantly prolonged OS in pts with high-risk MDS (Fenaux, Blood 2007;110,817)....